Legend Biotech Announces Compensation for Interim CEO Alan Bash

On August 6, 2026, Legend Biotech Corporation filed a Form 6-K announcing the compensation details for Alan Bash, who was recently appointed as the Company’s Interim Chief Executive Officer and interim principal executive officer, effective July 24, 2026. The Compensation Committee approved a bi-weekly cash payment of $12,019 for Mr. Bash, effective July 27, 2026. This interim compensation is in addition to his existing salary as President of the CARVYKTI Business Unit. Furthermore, the Board approved a one-time grant of restricted stock units (RSUs) valued at $50,000, to be granted on August 14, 2026. These RSUs are scheduled to vest in three equal annual installments beginning July 27, 2027, contingent upon his continued service with the company. This filing follows the initial announcement of his appointment made on July 27, 2026.